Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

Open access
O'Callaghan, G, Houston, A·2015·British Journal of Pharmacology

Abstract

Elevated expression of COX‐2 and increased levels of PGE 2 are found in numerous cancers and are associated with tumour development and progression. Although epidemiological, clinical and preclinical studies have shown that the inhibition of PGE 2 synthesis through the use of either non‐steroidal anti‐inflammatory drugs (NSAIDs) or specific COX‐2 inhibitors (COXibs) has the potential to prevent and treat malignant disease, toxicities due to inhibition of COX‐2 have limited their use. Thus, there is an urgent need for the development of strategies whereby COX‐2 activity may be reduced without inducing any side effects. The biological effects of PGE 2 are mediated by signalling through four distinct E‐type prostanoid (EP) receptors – EP 1, EP 2, EP 3 and EP 4. In recent years, extensive effort has gone into elucidating the function of PGE 2 and the EP receptors in health and disease, with the goal of creating selective inhibitors as a means of therapy. In this review, we focus on PGE 2, and in particular on the role of the individual EP receptors and their signalling pathways in neoplastic disease. As knowledge concerning the role of the EP receptors in cancer grows, so does the potential for exploiting the EP receptors as therapeutic targets for the treatment of cancer and metastatic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13331

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
O'Callaghan, G., & Houston, A.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2015-10-26
Volume
172
Issue
22
Pages
5239-5250
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1892430921
Cited by
176
References
1
FWCI
8.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.